State of New Jersey Common Pension Fund D Takes $821,000 Position in Apogee Therapeutics Inc. $APGE

State of New Jersey Common Pension Fund D bought a new stake in Apogee Therapeutics Inc. (NASDAQ:APGE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,879 shares of the company’s stock, valued at approximately $821,000.

A number of other large investors have also recently added to or reduced their stakes in APGE. ANTIPODES PARTNERS Ltd increased its stake in shares of Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after purchasing an additional 246 shares during the last quarter. Comerica Bank lifted its stake in Apogee Therapeutics by 1.0% in the 4th quarter. Comerica Bank now owns 35,872 shares of the company’s stock valued at $2,708,000 after purchasing an additional 338 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Apogee Therapeutics by 2.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Apogee Therapeutics by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,935 shares of the company’s stock worth $674,000 after purchasing an additional 853 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Apogee Therapeutics by 49.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,665 shares of the company’s stock worth $201,000 after buying an additional 882 shares during the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insiders Place Their Bets

In other news, insider Carl Dambkowski sold 5,500 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $84.14, for a total value of $462,770.00. Following the completion of the sale, the insider owned 207,023 shares of the company’s stock, valued at approximately $17,418,915.22. The trade was a 2.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $82.58, for a total transaction of $1,651,600.00. Following the completion of the transaction, the chief executive officer owned 1,132,987 shares in the company, valued at $93,562,066.46. This trade represents a 1.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 76,500 shares of company stock valued at $5,734,420 in the last three months. Insiders own 24.30% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on APGE shares. Rothschild & Co Redburn initiated coverage on Apogee Therapeutics in a research report on Friday, May 1st. They issued a “buy” rating and a $140.00 price objective for the company. BTIG Research reissued a “buy” rating and set a $137.00 target price on shares of Apogee Therapeutics in a report on Monday, March 23rd. Mizuho raised their price target on Apogee Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Canaccord Genuity Group lifted their price objective on shares of Apogee Therapeutics from $89.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Wedbush increased their price objective on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.73.

Apogee Therapeutics Trading Up 1.9%

Apogee Therapeutics stock opened at $84.60 on Tuesday. The company has a market capitalization of $5.23 billion, a price-to-earnings ratio of -20.05 and a beta of 0.69. Apogee Therapeutics Inc. has a 12 month low of $34.34 and a 12 month high of $95.32. The stock’s 50 day moving average is $80.24 and its 200-day moving average is $73.40.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings results on Monday, May 11th. The company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.06. As a group, equities research analysts predict that Apogee Therapeutics Inc. will post -4.57 earnings per share for the current fiscal year.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.